Chemotherapy in metastatic melanoma: phase II studies of amsacrine, mitoxantrone and bisantrene.
In a phase II study 20 patients with measurable metastatic melanoma were treated with amsacrine 120 mg/m2 every 3 weeks. No objective responses were observed. In a separate study 29 patients received mitoxantrone 12-14 mg/m2 every 3-4 weeks. One objective partial response was seen. The drug was well tolerated. Seventeen patients were treated with bisantrene 135-200 mg/m2 weekly. No objective responses were observed. Phlebitis was the major non-hematologic toxicity of bisantrene. These agents are not recommended for treatment of malignant melanoma.
D000609:Aminoacridines / Q000627:therapeutic use; D000677:Amsacrine; D000873:Anthracenes / Q000009:adverse effects / Q000627:therapeutic use; D000880:Anthraquinones / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D008942:Mitoxantrone; D010689:Phlebitis / Q000139:chemically induced; D012878:Skin Neoplasms / Q000188:drug therapy*
D000609:Aminoacridines; D000873:Anthracenes; D000880:Anthraquinones; D000970:Antineoplastic Agents; D000677:Amsacrine; C031404:bisantrene; D008942:Mitoxantrone